Aspirin resistance in children with heart disease at risk for thromboembolism: Prevalence and possible mechanisms

Pediatric Cardiology

Volumn 29, Issue 2, 2008, Pages 285-291

  Heistein, Lisa C ^a   Scott, William A ^a   Zellers, Thomas M ^a   Fixler, David E ^a   Ramaciotti, Claudio ^a   Journeycake, Janna M ^a   Lemler, Matthew S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aspirin; Congenital heart disease; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

ADOLESCENT; ASPIRIN; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; MALE; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TEXAS; THROMBOEMBOLISM; THROMBOXANE B2;

EID: 40949151608     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-007-9098-7     Document Type: Article

References (28)

1. 2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J 69:179-182
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jiminez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C (2006) Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97:38-43
3. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D (2005) Resistance to aspirin in increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thrombosis J 3:10
4. Bruno A, McConnell JP, Mansbach HH, Cohen SN, Tietjen GE, Bang NU (2002) Aspirin and urinary 11-dehydrothromboxane B2 in african american stroke patients. Stroke 33:57-60
5. Coakley M, Self R, Marchant W, Mackie I, Mallett SV, Mythen M (2005) Use of the platelet function analyzer (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia 60:1173-1178
6. Coma-Canella I, Velasco A, Castano S (2005) Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101:71-76
7. Djurup R, Chiabrando C, Jorres A, Fanelli R, Foegh M, Soerensen HU, Joergensen PN (1993) Rapid, direct enzyme immunoassay of 11-keto-thromboxane B2 in urine, validated by immunoaffinity/gas chromatography-mass spectrometry. Clin Chem 39:2470-2477
8. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Qilong, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655
9. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD (1998) Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31:352-358
10. Gross S, Keefer V, Liebman J (1968) The platelets in cyanotic congenital heart disease. Pediatrics 42(4):651-658
11. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
13. Gum PA, Kettke-Marchant K, Poggio ED Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
14. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland DJ, Brace LD (1993) Aspirin response and failure in cerebral infarction. Stroke 24:345-350
15. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of aspirin (ASA) pharmacodynamics with the Platelet Function Analyzer PFA-100. Thromb Haemost 83:316-321
16. Horigome H, Hiramatsu Y, Shigeta O, Nagasawa T, Matsui A (2002) Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol 39:1072-1077
17. Kierzkowska B, Stanczyk J, Wiectawska B, Rozalski M, Boncler M, Chrul S, Watala C (2001) Activation of circulating platelets and platelet response to activating agents in children with cyanotic congenital heart disease: their relevance to palliative systemic-pulmonary shunt. Int J Cardiol 79:49-59
18. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA (1995) Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hamost 21(Suppl 2):106-112
19. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:45-49
20. Mammen EF; Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin ES, Liles D, Nugent DJ (1998) PFA-100 system: a new method for assessment of platelet dysfunction. Sem Thromb Hemost 24(2):195-202
21. McKee SA, Sane DC, Deliargyris EN (2002) Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 88:711-715
22. Michelson AD, Cattaneo M, EIkelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK (2005) on behalf of the platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3:1309-1311
23. Odegard KC, McGowan FX Jr, Zurakowski D, DiNardo JA, Castro RA, del Nido PJ, Laussen PC (2002) Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. J Thorac Cardiovasc Surg 123:459-465
24. Pappas JM, Westengard JC, Bull BS (1994) Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 188:801-4
25. Rand ML, Carcao MD, Blanchette VS (1998) Use of the PFA-100 in the assessment of primary platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 24:523-529
26. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ (1998) Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97:350-355
27. Waldman JD, Czapek EE, Paul MH, Schwartz AD, Levin DL, Schindler S (1975) Shortened platelet survival in cyanotic heart disease. J Pediatr 87(1):77-79
28. Weber A, Przytulski B, Schanz A, Hohlfeld T, Schror K (2002) Towards a definition of aspirin resistance: a typological approach. Platelets 13:37-40